Kopran Limited has launched two new cardiovascular drugs - Caditone (carvedilol) for the treatment of hypertension and congestive cardiac failure (CCF) and Zeter (clopidrogrel) to prevent blockage of artery by clot formation (thrombosis).
Caditone is an internationally well-accepted cardiovascular drug, effective in the management of hypertension and congestive heart failure with a high safety profile. Caditone is the latest addition to beta-blocker group of drugs. Unlike conventional beta blocking drugs such as atenolol, it has the advantage of additional alpha-receptor blocking action and unique antioxidant properties. The drug offers better protection to heart, brain and kidneys.
The size of the anti-hypertensive and congestive cardiac failure (CCF) therapy segments in India is estimated to be around Rs .843 crore and Rs. 180.6 crore, respectively. The Anti-hypertensive segment is growing at 19 per cent and CCF segment at around 14 per cent.
Zeter is the latest anti-platelet drug useful for preventing thrombosis (blockade of artery by clot formation). The drug is used in the management of Acute Coronary Syndrome (fully developed or impending heart attack), Transient Ischemic Attack (impending stroke) and other similar vascular disease. The clinical trails have shown the drugs to be more effective and safer than aspirin.
The size of the anti-platelet market in India is around Rs. 80 crore growing at over 100 per cent.
To improve the access of these modern life saving drugs to a much wider patient population Kopran has launched Caditone and Zeter at a much affordable price to the patients. Each tablet of Caditone and Zeter costs Rs. 2.20 and Rs. 5.50, respectively to the patients, which is 25 per cent to 50 per cent less than the other carvedilol and clopidrogrel brands in India.